Key Points
- Executive vice president Simrat Randhawa sold 23,124 DNTH shares at an average price of $106.41, generating approximately $2.46 million. The sale reduced the executive’s ownership by 85.25%, leaving 4,000 shares.
- Dianthus Therapeutics shares opened at $107.85, near their 12-month high of $117.88, while the company reported a quarterly loss of $0.90 per share—worse than analysts’ $0.85 estimate—despite revenue exceeding expectations.
- Analysts remain broadly positive, with a consensus “Moderate Buy” rating and an average price target of $124.27; institutional investors own 47.53% of the company.
Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) EVP Simrat Randhawa sold 23,124 shares of the business's stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $106.41, for a total transaction of $2,460,624.84. Following the completion of the sale, the executive vice president owned 4,000 shares in the company, valued at $425,640. This represents a 85.25% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Dianthus Therapeutics Trading Up 1.5%
NASDAQ:DNTH opened at $107.85 on Friday. The company has a market capitalization of $5.90 billion, a P/E ratio of -25.99 and a beta of 1.24. The firm has a 50-day moving average price of $104.98 and a two-hundred day moving average price of $88.94. Dianthus Therapeutics, Inc. has a twelve month low of $23.70 and a twelve month high of $117.88.
Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.05). Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. The business had revenue of $0.76 million during the quarter, compared to analyst estimates of $0.30 million. On average, equities research analysts predict that Dianthus Therapeutics, Inc. will post -3.83 earnings per share for the current year.
Wall Street Analyst Weigh In
DNTH has been the subject of several recent research reports. Raymond James Financial reissued a "strong-buy" rating and set a $131.00 price target on shares of Dianthus Therapeutics in a research report on Wednesday, August 5th. TD Cowen restated a "buy" rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Wall Street Zen raised Dianthus Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, May 9th. Guggenheim reiterated a "buy" rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Finally, Wedbush boosted their target price on shares of Dianthus Therapeutics from $105.00 to $122.00 and gave the company an "outperform" rating in a research note on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Dianthus Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $124.27.
Get Our Latest Analysis on DNTH
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Raymond James Financial Inc. purchased a new stake in Dianthus Therapeutics during the second quarter valued at about $27,000. First Horizon Corp acquired a new stake in Dianthus Therapeutics during the first quarter worth about $32,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Dianthus Therapeutics in the 4th quarter worth about $40,000. EFG International AG acquired a new position in shares of Dianthus Therapeutics in the 2nd quarter valued at about $49,000. Finally, Russell Investments Group Ltd. acquired a new position in shares of Dianthus Therapeutics in the 3rd quarter valued at about $64,000. Institutional investors and hedge funds own 47.53% of the company's stock.
About Dianthus Therapeutics
(
Get Free Report)
Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
